Last reviewed 2026-04-20 · How we verify

Valbil (FEBUPROL)

Phase 2 active Small molecule

Valbil (generic name: FEBUPROL) is a febuprol drug. It is currently in Phase 2 development.

Valbil is thought to work by interacting with a specific biological target, although the exact mechanism is not well understood.

Valbil (FEBUPROL) is a small molecule drug of the febuprol class, but specific details about its development, ownership, and commercial status are not available. Its target and mechanism of action are also unknown. As a result, there is limited information available on its approved indications, half-life, bioavailability, and generic manufacturers. Further research is needed to determine its safety profile and potential therapeutic applications. Overall, Valbil's clinical utility and pharmacological properties remain unclear.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	FEBUPROL
Drug class	febuprol
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells have locks on them, and Valbil is a key that fits into those locks. When it binds to the lock, it can either block or enhance the activity of the cell, depending on the type of lock and the key's shape. This interaction can affect various cellular processes, leading to changes in the body's response to different stimuli.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Valbil CI brief — competitive landscape report
Valbil updates RSS · CI watch RSS

Frequently asked questions about Valbil

What is Valbil?

Valbil (FEBUPROL) is a febuprol drug.

How does Valbil work?

Valbil is thought to work by interacting with a specific biological target, although the exact mechanism is not well understood.

What is the generic name of Valbil?

FEBUPROL is the generic (nonproprietary) name of Valbil.

What drug class is Valbil in?

Valbil belongs to the febuprol class. See all febuprol drugs at /class/febuprol.

What development phase is Valbil in?

Valbil is in Phase 2.

Drug class: All febuprol drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing